AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
Subscribe To Our Newsletter & Stay Updated